亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Low-dose Olanzapine and Sertraline Combination Therapy for Metabolic Disturbance in Patients with Schizophrenia: A Large-scale, Open-label Randomized Trial

奥氮平 医学 联合疗法 随机对照试验 舍曲林 扰动(地质) 麻醉 内科学 药理学 药物治疗 临床试验
作者
Xiaoni Guan,Meihong Xiu,Fengchun Wu
出处
期刊:Current Neuropharmacology [Bentham Science Publishers]
卷期号:23
标识
DOI:10.2174/011570159x395131251008050155
摘要

INTRODUCTION: Olanzapine-associated metabolic adverse effects lead to medication discontinuation and non-compliance in Schizophrenia (SCZ). This study aimed to examine the efficacy of a low dose of olanzapine in combination with sertraline in mitigating metabolic adverse effects by reducing the olanzapine dose in first-episode SCZ (FE-SCZ) patients. METHODS: This randomized clinical trial with a blinded endpoint design was conducted among FESCZ patients. During a 12-week treatment, 196 patients with FE-SCZ were randomly assigned to the combined low-dose olanzapine/sertraline (OS group) or standard-dose olanzapine (control group). The body weight and levels of fasting glucose and blood lipids were determined at baseline and the end of weeks 4, 8, 12, and 24. Additionally, the clinical symptoms were also assessed at baseline and follow-up. RESULTS: Relative to the control group, the OS group had a lower percentage of weight gain from baseline to week 24 across two thresholds (7% and 10%) for changes in bodyweight (100% vs. 97.8%; 98.7% vs. 28.3%). In addition, combination treatment mitigated olanzapine-associated weight gain and other metabolic abnormalities compared with the control group (all p < 0.01). Notably, clinical symptom improvements were similar between the two treatment groups. DISCUSSION: Our study suggests that low-dose olanzapine/sertraline combination therapy was correlated with significantly less weight gain and improved other metabolic parameter levels than standard- dose olanzapine in patients with FE-SCZ. Clinical symptom improvements in the combination group were comparable to those of the olanzapine monotherapy group. CONCLUSION: These findings suggest a potential strategy to improve medication adherence and overall patient outcomes by mitigating metabolic side effects. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04076371.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稳重若男完成签到,获得积分10
4秒前
微笑的天抒完成签到,获得积分0
5秒前
我是老大的应助被Ruan采纳,获得10
17秒前
25秒前
迷路的皮皮虾完成签到,获得积分10
30秒前
Ruan发布了新的文献求助10
31秒前
兴奋的惮完成签到,获得积分10
34秒前
热爱科研的小海豹完成签到 ,获得积分10
37秒前
欢喜的铭完成签到,获得积分10
47秒前
1分钟前
高高的城发布了新的文献求助10
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
彭于晏的应助被高高的城采纳,获得10
1分钟前
清爽的天川完成签到,获得积分10
1分钟前
1分钟前
1分钟前
呆萌雨完成签到,获得积分10
1分钟前
大胆蛟凤完成签到,获得积分10
2分钟前
迷人白桃完成签到,获得积分10
2分钟前
2分钟前
楓秋完成签到 ,获得积分10
2分钟前
mmyhn驳回了奔跑的应助
2分钟前
爱听歌鲂完成签到,获得积分10
2分钟前
2分钟前
3分钟前
英俊的铭的应助被科研通管家采纳,获得10
3分钟前
忧虑的怀曼完成签到,获得积分10
3分钟前
顺心安雁完成签到,获得积分10
3分钟前
李佳佳发布了新的文献求助10
3分钟前
mmyhn驳回了奔跑的应助
3分钟前
大熊完成签到 ,获得积分10
3分钟前
qin完成签到 ,获得积分10
3分钟前
3分钟前
光亮豌豆完成签到,获得积分10
3分钟前
无私的迎蓉完成签到,获得积分10
3分钟前
3分钟前
4分钟前
4分钟前
每天吃土发布了新的文献求助10
4分钟前
奔跑的应助被mmyhn采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173088
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780437
捐赠科研通 7767172
什么是DOI,文献DOI怎么找? 3431536
关于科研通互助平台的介绍 2555678
邀请新用户注册赠送积分活动 2476675